N'-[1-(4-Methoxyphenyl)ethylidene]acetohydrazide | 14850-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N'-[1-(4-Methoxyphenyl)ethylidene]acetohydrazide
• 英文别名: N-[(E)-1-(4-methoxyphenyl)ethylideneamino]acetamide
• CAS: 14850-50-1
• 化学式: C₁₁H₁₄N₂O₂
• 分子量: 206.24
• InChiKey: QOCZPPHVOJRFHR-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N'-[1-(4-Methoxyphenyl)ethylidene]acetohydrazide 、 甲醇 、 lead(IV) acetate 以40%的产率得到
  参考文献：
  名称：

  BEKHAZI, M.;SMITH, P. J.;WARKENTIN, J., CAN. J. CHEM., 1984, 62, N 8, 1646-1652

  摘要：

  DOI：

文献信息

• Charged linkers and their uses for conjugation
  申请人：HANGZHOU DAC BIOTECH CO., LTD.

  公开号：US10683314B2

  公开（公告）日：2020-06-16

  Cell binding agent-drug conjugates comprising phosphinate-based charged linkers and methods of using such linkers and conjugates are provided.

  提供了包含膦酸酯基带电连接体的细胞结合剂-药物共轭物以及使用这种连接体和共轭物的方法。
• ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US20200397916A1

  公开（公告）日：2020-12-24

  The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.
• HETEROCYCLIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US20210106694A1

  公开（公告）日：2021-04-15

  The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics. Specifically claimed are: (1) compounds containing reactive functional groups (compound of formula I), compounds containing compounds to be linked together (compound of formula II) and compounds having a reactive functional group/a compound to be linked (compound of formula IV), (2) an antibody-drug conjugate (compound of formula III), wherein the antibody is covalently attached by a linker to one or more drugs, (3) pharmaceutical compositions comprising compounds of Formula (II) or Formula (III), (4) treatment/diagnosis of disease comprising compounds of Formula (II) or Formula (III), and (5) methods of preparing an ADC of Formula III.